Korean Distributor, Global Damon Pharma, to Launch Maxisal(R) Marketing
Campaign in January 2004
Amarillo Continues to Pursue Bio-Terrorism Agenda; Corporate Sponsorship For
CDAD Underway
AMARILLO, Texas, Nov. 18 /PRNewswire-FirstCall/ -- Amarillo Biosciences
Inc. (OTC Bulletin Board: AMAR) (ABI) and Global Damon Pharma (GDP), ABI's
Korean pharmaceutical distributor announce that Maxisal(R) with vitamin C has
received regulatory approval for marketing in Korea. Maxisal(R) is a
pharmaceutical grade of anhydrous crystalline maltose made exclusively by
Hayashibara Biochemical Laboratories of Okayama, Japan and marketed for relief
of dry mouth.
Mr. D.K. Kim, President, GDP said, "We will start marketing Maxisal(R)
with vitamin C in January 2004 to patients with Sjogren's syndrome and kidney
dialysis patients. GDP will be conducting a study of Maxisal(R) in Singapore
in dialysis patients. We expect Maxisal(R) to help quench the thirst of
dialysis patients and result in less fluid intake. We think Maxisal(R) can
help reduce fluid retention, a huge problem in dialysis patients." "We are
delighted that GDP is our distributor in Korea and we are expanding the GDP
territory to include Thailand, Vietnam, Singapore, Malaysia, Indonesia,
Brazil, Rumania, and Poland," said Dr. Joseph Cummins, President, ABI.
Separately, the Company announced that it is in discussions with a large
agricultural company and two other potential sponsors regarding funding of the
Committee to Develop an Alternative to Depopulation (CDAD). CDAD is composed
of industry, university and government experts on epidemiology, immunology,
animal nutrition, virology, biostatistics, pathology and animal production.
The charter of the CDAD is to explore alternate means of responding to an
agricultural terrorism threat to livestock. Currently, the USDA's proposed
response to an infection such as foot-and-mouth disease -- a highly contagious
disease -- involves the mass slaughter and disposal of infected animals, a
solution that could potentially cost the economy billions of dollars and have
devastating environmental consequences.
About Amarillo Biosciences, Inc.
Amarillo Biosciences, is a biotechnology firm operating in global
partnership with the Hayashibara Group, which also holds 32% of ABI's shares.
The Company's primary focus is extensive R&D into the use of low-dose, orally
administered interferon as a treatment for a variety of conditions, including
opportunistic infections in patients who are HIV positive. Additional
information is available on the ABI web site at http://www.amarbio.com .
Except for the historical information contained herein, the matters
discussed in this news release are forward-looking statements that involve
risks and uncertainties, including uncertainties related to product
development, the need for regulatory and other government approvals,
dependence on proprietary technology, uncertainty of market acceptance of oral
interferon or the Company's other products and other risks detailed from time
to time in the Company's filings with the Securities and Exchange Commission.
In particular, see "Item 1. Description of Business' of the Company's Form
10-KSB for the year ended December 31, 2002."
SOURCE Amarillo Biosciences, Inc.
 back to top
Related links:
http://www.amarbio.com
Company News On-Call:
http://www.prnewswire.com/comp/118055.html
CONTACT:
Dr. Joseph M. Cummins, President & CEO of
Amarillo Biosciences, Inc., +1-806-376-1741, ext. 13, or
jcummins@amarbio.com ; or Philippe Niemetz of WPH Consultants
Ltd., +1-800-477-7570, or +1-212-344-6464, or
philippe.niemetz@wphconsultants.com , for Amarillo Biosciences,
Inc.
|
